Potentially radioactive shrimp recalled at Walmarts in a dozen states
Why it matters: This is not your chance to develop amazing crustacean-based superpowers. Any prolonged exposure to radiation could cause sickness or even death.
Driving the news: The FDA said Tuesday that certain types of Great Value raw frozen shrimp sold at Walmart may be contaminated with Cesium-137, a radioactive isotope.
U.S. Customs and Border Protection initially told the FDA that Cesium-137 had been detected in containers at four different U.S. ports, the FDA said.
The FDA then found the isotope in one sample of breaded shrimp.
Indonesia's BMS Foods allegedly violated the Federal Food, Drug, and Cosmetic Act, the FDA said, because the product "appears to have been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with Cs-137 and may pose a safety concern."
Yes, but: No shrimp that tested positive for the radioactive isotope have entered the U.S. commerce supply, according to the FDA.
All products from BMS are banned "from coming into the U.S. until the firm has resolved the conditions that gave rise to the appearance of the violation," the FDA said.
Worth noting: The FDA oversees safety of both domestic and imported seafood. The agency seeks out any immediate or potential threats when assessing products for safety.
Which Walmart shrimp products are radioactive?
Zoom in: The FDA shared three Great Value products that should not be shared, eaten or served to others:
Great Value brand frozen raw shrimp, lot code: 8005540-1, Best by Date: March 15, 2027
Great Value brand frozen raw shrimp, lot code: 8005538-1, Best by Date: March 15, 2027
Great Value brand frozen raw shrimp, lot code: 8005539-1, Best by Date: March 15, 2027
Context: These were sold at stores in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia, according to the FDA.
Walmart told Axios in an email Tuesday that it recalled the product from impacted stores and customers who purchased the shrimp are eligible for a full refund.
"The health and safety of our customers is always a top priority," Kelly Hellbusch, a Walmart spokesperson, said in a statement. "We have issued a sales restriction and removed this product from our impacted stores. We are working with the supplier to investigate."
Symptoms of radiation from shrimp, Cesium-137
The FDA said the amount of Cesium-137 found in the shipment was low enough that it "would not pose an acute hazard to consumers."
However, the warning "is a measure intended to reduce exposure to low-level radiation that could have health impacts with continued exposure over a long period of time," the FDA said.
According to the Environmental Protection Agency, ingesting Cesium-137 can increase the risk of cancer.
What to do with recalled Walmart shrimp
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Court Victory and Fresh Funding Propel Growth at Liquidia Corporation
Liquidia Corporation (NASDAQ:LQDA) is one of the 11 Best Short Squeeze Stocks to Buy Now. Price targets raised by analysts following a favorable court ruling and receipt of funding under the HCR agreement. An aerial view of a biopharmaceutical manufacturing plant, signifying the company's expansive operations. Located in North Carolina, Liquidia Corporation (NASDAQ:LQDA) develops and commercializes treatments for rare cardiopulmonary diseases. With YUTREPIA™ (inhaled treprostinil powder) as its lead product, the company gained FDA approval for its use in the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. For targeted drug delivery, the company leverages proprietary PRINT® nanoparticle technology. Following a favorable court ruling, Liquidia Corporation (NASDAQ:LQDA) commenced the first commercial sale of its pulmonary hypertension treatment, YUTREPIA™, and received an additional $50 million under its sixth amendment to its financing agreement (HCR Agreement) with Healthcare Royalty (HCRx). Liquidia Corporation (NASDAQ:LQDA) has so far received a total of $175 million of the $200 million in potential funding, as per the HCR agreement terms. If the company manages an aggregate net sale of YUTREPIA of more than $100 million at any time on or prior to June 30, 2026, it could receive an additional $25million based on mutual agreement between the parties. Following these developments, many analysts have raised the price target on the company's stock. For instance, Bank of America recently raised the price target from $23 to $35, signaling a strong confidence in the company's growth potential. The short float of 32.39% creates a potential for rapid upside for Liquidia Corporation (NASDAQ:LQDA)'s shareholders, in the event of positive catalysts. While we acknowledge the potential of LQDA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 12 Best REIT Stocks to Buy Right Now and 10 Stocks with Huge Catalysts on the Horizon Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 minutes ago
- Yahoo
Regulatory Milestone and Analyst Optimism Fuel Momentum for Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is one of the 11 Best Short Squeeze Stocks to Buy Now. The company's stocks surge following the approval of the U.S. FDA Priority Review for sNDA for Revuforj (revumenib). A scientist in a laboratory testing a monoclonal antibody for the treatment of cancer. Headquartered in Massachusetts, Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is a commercial-stage oncology company engaged in developing novel combination therapies for cancer. The lead products include Revumenib, a menin inhibitor for acute leukemia, and Niktimvo (axatilimab-csfr) for chronic graft-versus-host disease. Currently, the company's clinical pipeline also looks into applications in solid tumors and inflammatory conditions. On June 24, 2025, Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) announced receiving a U.S. FDA Priority Review for its supplemental New Drug Application (sNDA) for Revuforj (revumenib) for the treatment of relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia (AML). This sNDA, reviewed under the FDA's Real-Time Oncology Review (RTOR) program, allows for a more efficient review and close engagement between the sponsor and FDA. The Prescription Drug User Fee Act (PDUFA) target action date is October 25, 2025. Following the announcements, many analysts have reiterated their Buy rating on the stock. The 1-year median price target for the stock, as per CNN's 12 analysts, is $35, a 169.85% uptick from its current closing price as of August 12, 2025. Also, the company's stocks are vulnerable to sudden price surges on positive news, with an elevated short float of 28.69% that tends to heighten the risk for short sellers. While we acknowledge the potential of SNDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 12 Best REIT Stocks to Buy Right Now and 10 Stocks with Huge Catalysts on the Horizon Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Target's CEO is stepping down as customers turn away
Target CEO Brian Cornell is stepping down after 11 years at the retailer, as the company faces slumping sales and backlash to its retreat on DEI. Cornell's departure was widely expected. Some industry analysts believed Target should bring in an outside voice to lead the company, but it opted for an internal candidate: Cornell will be replaced on February 1, 2026, by Michael Fiddelke, Target's current chief operating officer. Fiddelke started as an intern at Target and has been at the company for 20 years. Cornell will stay on as executive chairman. He took over in 2014 and revitalized Target. He oversaw a strategy to remodel stores and strengthen the chain's online business to compete with Amazon. But Target has been in a deep slump for years, a result largely of its own strategic missteps. The company has also struggled as customers have purchased less of its home goods and clothing, and Target has faced intense competition from Walmart, Amazon and Costco. Target on Wednesday reported sales fell for the third-straight quarter. Shares fell 10% in premarket trading. Target's (TGT) stock is among the worst performing companies in the S&P 500 this year. Some analysts criticized Target's board choosing an insider and said the company should have gone further. 'This an internal appointment that does not necessarily remedy the problems of entrenched groupthink and the inward-looking mindset that have plagued Target for years,' Neil Saunders, an analyst at GlobalData Retail, said in a note to clients Wednesday. 'Target, which used to be very attuned to consumer demand, has lost its grip on delivering for the American shopper.' DEI retreat and shopper slowdown The last three years have been unkind to target, but 2025 has been particularly tumultuous. Earlier this year, the company ended some of its DEI programs. The decision angered supporters of diversity and inclusion policies, who felt blindsided by Target. Customers online protested Target's decision and Anne and Lucy Dayton, the daughters of one of Target's co-founders, called the company's actions 'a betrayal.' Target acknowledged its move hurt its sales. Target came under more pressure than other companies that rolled back DEI policies because Target had more deeply ingrained diversity and inclusion programs into the core of its business. Target also has a more progressive base of customers than many competitors. Tariffs and a consumer slowdown have put even more pressure on Target. Target is known for its trendier items and chain stocks more nonessential merchandise than competitors. More than half of Target's merchandise is discretionary. But that merchandise has slumped as shoppers spend more on essentials such as food and household basics. Around half of Walmart's business, for example, comes from groceries. Target also imports around half of its merchandise, compared to roughly 33% at Walmart, so it needs to raise prices at almost double the rate of Walmart to mitigate the tariff impact, Bank of America analyst Robert Ohmes said in a report this week. Analysts are mixed as to whether Target's issues are easily solvable or if drastic changes are necessary to revive to the business. 'Target's long-term outlook is deteriorating,' Ohmes said. 'Target is falling behind peers and has tougher challenges.' Rocky tenure Target's recent struggles are a reversal of Cornell's early years at the retailer. In 2018, Target reported its best results in a decade. The following year, Cornell was named CNN Business' CEO of the Year for leading a turnaround at Target. The company thrived at a time when many brick-and-mortar stores were closing. 'Target has earned a place in the retail winners' circle by investing in our business and staying true to our guests and our purpose,' Cornell told CNN in 2019. Target boomed during the pandemic in 2020 and 2021 as shoppers rushed to stores to purchase essentials, home goods, office supplies and other merchandise. The company's home goods also proved popular as stuck-at-home Americans looked to improve their living spaces when they couldn't venture outside. But Target began to falter in 2022. The chain bought too much merchandise and dealt with a glut of unsold inventory as decades-high inflation pressured many of its shoppers. Post-pandemic, shoppers stopped buying up treadmills, TVs and home goods – especially as inflation started to bite. A year later, activists and customers on the right attacked Target on social media for its LGBTQ-themed merchandise during Pride Month. Target employees faced threats over items such as bathing suits designed for transgender people, and the company removed them from stores. Misinformation spread on social media that the swimsuits were marketed to children, which they were not. The backlash led to a drop in sales and lawsuits from Republican-aligned legal groups. This is a breaking news story and will be updated.
